| GBM | Glioblastoma |
| GSCs | Glioblastoma Stem Cells |
| CNS | Central Nervous System |
| NSCs | Neural Stem Cells |
| WHO | World Health Organization |
| MGMT | Methylation O6-methylguanine-DNA Methyl-transferase |
| IDH1 | IDH2 Isocitrate Dehydrogenase Isozymes 1 and 2 |
| EGFR | Epidermal Growth Factor Receptor |
| RTs | Radiation therapies |
| TMZ | Temozolomide |
| CSCs | Cancer Stem Cells |
| VEGF | Vascular Endothelial Growth Factor |
| Eph | Erythropoietin-Producing Hepatocellular Carcinoma Receptors |
| SFKs | Src Family Members of Protein Tyrosine Kinases |
| CBRs | Cannabinoid Receptors |
| 5-ALA | 5-aminolevulinic Acid |
| FDA | US Food and Drug Administration |
| BCNU | Carmustine |
| TTFields | Tumor-Treating Fields |
| PFS | Progression-Free Survival |
| OS | Overall Survival |
| BBB | Blood–Brain Barrier |
| CCNU | Lomustine |
| ACNU | Nimustine |
| FOT | Fotemustine |
| GSIs | γ-secretase inhibitors |
| ECM | Extracellular Matrix |
| PLAGL2 | Pleomorphic adenoma gene-like 2 |
| RYK | Receptor-like tyrosine kinase |
| ASCL1 | Achaete-scute homolog 1 |
| ECs | Endothelial cells |
| TME | Tumor Microenvironment |
| TAMs | Tumor-Associated Macrophages |
| POSTN | Periostin |